JP2011503075A - エポチロンまたはエポチロン誘導体誘発下痢を処置するためのコルチコステロイド - Google Patents
エポチロンまたはエポチロン誘導体誘発下痢を処置するためのコルチコステロイド Download PDFInfo
- Publication number
- JP2011503075A JP2011503075A JP2010533139A JP2010533139A JP2011503075A JP 2011503075 A JP2011503075 A JP 2011503075A JP 2010533139 A JP2010533139 A JP 2010533139A JP 2010533139 A JP2010533139 A JP 2010533139A JP 2011503075 A JP2011503075 A JP 2011503075A
- Authority
- JP
- Japan
- Prior art keywords
- epothilone
- antidiarrheal
- treatment
- prednisolone
- epothilone derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003883 epothilone derivatives Chemical class 0.000 title claims abstract description 65
- 239000003246 corticosteroid Substances 0.000 title claims abstract description 25
- 206010012735 Diarrhoea Diseases 0.000 title claims description 48
- 229930013356 epothilone Natural products 0.000 title claims description 7
- 229960001334 corticosteroids Drugs 0.000 title abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 38
- 230000001142 anti-diarrhea Effects 0.000 claims abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 239000003862 glucocorticoid Substances 0.000 claims abstract description 19
- 230000002062 proliferating effect Effects 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 47
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical group C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims description 35
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims description 33
- 229960005205 prednisolone Drugs 0.000 claims description 33
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229960004618 prednisone Drugs 0.000 claims description 15
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims description 11
- 229960003957 dexamethasone Drugs 0.000 claims description 11
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 11
- 150000003839 salts Chemical group 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003908 antipruritic agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000003793 antidiarrheal agent Substances 0.000 abstract description 15
- 229940125714 antidiarrheal agent Drugs 0.000 abstract description 12
- 150000003431 steroids Chemical class 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 description 33
- 241000700159 Rattus Species 0.000 description 26
- 229950007460 patupilone Drugs 0.000 description 21
- 239000002552 dosage form Substances 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 206010033128 Ovarian cancer Diseases 0.000 description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 8
- 206010009944 Colon cancer Diseases 0.000 description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010041067 Small cell lung cancer Diseases 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 201000010536 head and neck cancer Diseases 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000001954 papillon Nutrition 0.000 description 2
- 244000229285 papillon Species 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 1
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 108010046780 hydrocortisone receptor Proteins 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98663507P | 2007-11-09 | 2007-11-09 | |
| PCT/US2008/079936 WO2009061587A1 (en) | 2007-11-09 | 2008-10-15 | Corticosteroids to treat epothilone or epothilone derivative induced diarrhea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011503075A true JP2011503075A (ja) | 2011-01-27 |
| JP2011503075A5 JP2011503075A5 (enExample) | 2011-12-01 |
Family
ID=40087318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533139A Pending JP2011503075A (ja) | 2007-11-09 | 2008-10-15 | エポチロンまたはエポチロン誘導体誘発下痢を処置するためのコルチコステロイド |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100267682A1 (enExample) |
| EP (1) | EP2222286A1 (enExample) |
| JP (1) | JP2011503075A (enExample) |
| KR (1) | KR20100096077A (enExample) |
| CN (1) | CN101848708B (enExample) |
| AU (1) | AU2008325016A1 (enExample) |
| BR (1) | BRPI0820338A2 (enExample) |
| CA (1) | CA2703792A1 (enExample) |
| MX (1) | MX2010005119A (enExample) |
| RU (1) | RU2010123028A (enExample) |
| WO (1) | WO2009061587A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019131577A (ja) * | 2013-01-15 | 2019-08-08 | アラゴン ファーマシューティカルズ，インコーポレイテッド | アンドロゲン受容体調節剤及びその使用 |
| US10799489B2 (en) | 2012-09-26 | 2020-10-13 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| US11160796B2 (en) | 2017-10-16 | 2021-11-02 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109790584A (zh) * | 2016-09-27 | 2019-05-21 | 梅奥医学教育及研究基金会 | 用于评价和治疗癌症的材料和方法 |
| US10705435B2 (en) | 2018-01-12 | 2020-07-07 | Globalfoundries Inc. | Self-referencing and self-calibrating interference pattern overlay measurement |
| US11686576B2 (en) | 2020-06-04 | 2023-06-27 | Kla Corporation | Metrology target for one-dimensional measurement of periodic misregistration |
| US11796925B2 (en) | 2022-01-03 | 2023-10-24 | Kla Corporation | Scanning overlay metrology using overlay targets having multiple spatial frequencies |
| US12032300B2 (en) | 2022-02-14 | 2024-07-09 | Kla Corporation | Imaging overlay with mutually coherent oblique illumination |
| US12422363B2 (en) | 2022-03-30 | 2025-09-23 | Kla Corporation | Scanning scatterometry overlay metrology |
| US12487190B2 (en) | 2022-03-30 | 2025-12-02 | Kla Corporation | System and method for isolation of specific fourier pupil frequency in overlay metrology |
| US12235588B2 (en) | 2023-02-16 | 2025-02-25 | Kla Corporation | Scanning overlay metrology with high signal to noise ratio |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006010585A1 (en) * | 2004-07-26 | 2006-02-02 | Novartis Ag | Epothilone combinations |
| JP2006504727A (ja) * | 2002-10-11 | 2006-02-09 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 多発性骨髄腫の処置のためのラクトン誘導体 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1231894A (zh) * | 1998-04-14 | 1999-10-20 | 陈水清 | 止泻栓 |
| DE60229922D1 (de) * | 2001-03-19 | 2009-01-02 | Novartis Ag | Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend |
| US6974818B2 (en) * | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
-
2008
- 2008-10-15 CN CN2008801149548A patent/CN101848708B/zh not_active Expired - Fee Related
- 2008-10-15 EP EP08848076A patent/EP2222286A1/en not_active Withdrawn
- 2008-10-15 WO PCT/US2008/079936 patent/WO2009061587A1/en not_active Ceased
- 2008-10-15 JP JP2010533139A patent/JP2011503075A/ja active Pending
- 2008-10-15 MX MX2010005119A patent/MX2010005119A/es not_active Application Discontinuation
- 2008-10-15 BR BRPI0820338A patent/BRPI0820338A2/pt not_active IP Right Cessation
- 2008-10-15 RU RU2010123028/15A patent/RU2010123028A/ru not_active Application Discontinuation
- 2008-10-15 US US12/741,680 patent/US20100267682A1/en not_active Abandoned
- 2008-10-15 AU AU2008325016A patent/AU2008325016A1/en not_active Abandoned
- 2008-10-15 KR KR1020107010102A patent/KR20100096077A/ko not_active Withdrawn
- 2008-10-15 CA CA2703792A patent/CA2703792A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006504727A (ja) * | 2002-10-11 | 2006-02-09 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 多発性骨髄腫の処置のためのラクトン誘導体 |
| WO2006010585A1 (en) * | 2004-07-26 | 2006-02-02 | Novartis Ag | Epothilone combinations |
| JP2008507573A (ja) * | 2004-07-26 | 2008-03-13 | ノバルティス アクチエンゲゼルシャフト | エポチロン組合せ剤 |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10799489B2 (en) | 2012-09-26 | 2020-10-13 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| US10849888B2 (en) | 2012-09-26 | 2020-12-01 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| USRE49353E1 (en) | 2012-09-26 | 2023-01-03 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| USRE50642E1 (en) | 2012-09-26 | 2025-10-21 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| JP2019131577A (ja) * | 2013-01-15 | 2019-08-08 | アラゴン ファーマシューティカルズ，インコーポレイテッド | アンドロゲン受容体調節剤及びその使用 |
| US11160796B2 (en) | 2017-10-16 | 2021-11-02 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| US11491149B2 (en) | 2017-10-16 | 2022-11-08 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009061587A1 (en) | 2009-05-14 |
| US20100267682A1 (en) | 2010-10-21 |
| CA2703792A1 (en) | 2009-05-14 |
| AU2008325016A1 (en) | 2009-05-14 |
| CN101848708B (zh) | 2013-01-02 |
| CN101848708A (zh) | 2010-09-29 |
| RU2010123028A (ru) | 2011-12-20 |
| BRPI0820338A2 (pt) | 2017-05-02 |
| KR20100096077A (ko) | 2010-09-01 |
| EP2222286A1 (en) | 2010-09-01 |
| MX2010005119A (es) | 2010-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503075A (ja) | エポチロンまたはエポチロン誘導体誘発下痢を処置するためのコルチコステロイド | |
| JP6904640B2 (ja) | 癌の処置 | |
| JP2022185091A (ja) | 癌を治療するための方法及び組成物 | |
| JP7033642B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤 | |
| JP2007525440A (ja) | アルドステロン受容体アンタゴニストおよび抗糖尿病剤の組合せ | |
| JP2007525440A6 (ja) | アルドステロン受容体アンタゴニストおよび抗糖尿病剤の組合せ | |
| JP2011503075A5 (enExample) | ||
| TW200529861A (en) | Methods and reagents for the treatment of inflammatory disorders | |
| KR20040091141A (ko) | 알도스테론 수용체 길항물질 및 니코틴산 또는 니코틴산유도체의 혼합물 | |
| US6274621B1 (en) | Ginkgolides for inhibition of membrane expression of benzodiazepine receptors | |
| KR20040107481A (ko) | 알도스테론 수용체 길항물질 및 담즙산 격리제의 혼합물 | |
| US20080262071A1 (en) | Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder | |
| EP1485090B1 (en) | Combinations comprising an epothilone derivative and an imidazotetrazinone | |
| KR20250102046A (ko) | 다주코릴란트를 이용한 근위축성 측삭경화증의 치료 | |
| WO2006010085A1 (en) | Use of neurosteroids to treat neuropathic pain | |
| KR20250144469A (ko) | 헌팅턴병 및 이의 증상을 치료하기 위한 방법 및 조성물 | |
| KR20040107482A (ko) | 알도스테론 수용체 길항물질 및 피브르산 유도체의 혼합물 | |
| HK1072723B (en) | Combinations comprising an epothilone derivatives and an imidazotetrazinone | |
| HK1198946B (en) | Combination of a rapamycin derivative and letrozole for treating breast cancer | |
| HK1146247B (en) | Treatment of breast tumors with a rapamycin derivative in combination with exemestane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111014 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111014 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130528 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131022 |